Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7

BACKGROUND: Although the efficacy of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) against metastatic colorectal cancer (mCRC) has been demonstrated, little is known about its effectiveness upon disease stratification by RAS mutations. In this phase II study, we investigated the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, T., Yamazaki, K., Oki, E., Shiozawa, M., Mitsugi, K., Makiyama, A., Nakamura, M., Ojima, H., Kagawa, Y., Matsuhashi, N., Okuda, H., Asayama, M., Yuasa, Y., Shimada, Y., Manaka, D., Watanabe, J., Oba, K., Yoshino, T., Yoshida, K., Maehara, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985393/
https://www.ncbi.nlm.nih.gov/pubmed/33744811
http://dx.doi.org/10.1016/j.esmoop.2021.100093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985393/
https://www.ncbi.nlm.nih.gov/pubmed/33744811
http://dx.doi.org/10.1016/j.esmoop.2021.100093

Ejemplares similares